Skip to main content

AtriCure, Inc. (ATRC) Stock Forecast 2025 - AI Price Prediction & Analysis


AtriCure, Inc. (ATRC) AI Stock Price Forecast & Investment Analysis

AtriCure, Inc. Stock Price Chart and Technical Analysis

Loading AtriCure, Inc. interactive price chart and technical analysis...

AtriCure, Inc. (ATRC) - Comprehensive Stock Analysis & Investment Research

Deep dive into AtriCure, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about AtriCure, Inc., including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For AtriCure, Inc.: AtriCure, Inc. operates in the Industrial Applications and Services sector, making it an emerging small-cap investment.

AtriCure, Inc. (Stock Symbol: ATRC) is a leading company in the Industrial Applications and Services sector , specifically operating within the Surgical & Medical Instruments & Apparatus industry.

The organization employs approximately 1064 professionals worldwide .

The company has established itself as an emerging investment opportunity with substantial growth potential.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing AtriCure, Inc.'s revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For AtriCure, Inc.: With $499M in annual revenue and -75.1% net margin, the company demonstrates developing profitability.

Annual Revenue: $499 million generating a -75.1% net profit margin .

Market Capitalization: $1857 million - Classified as a small-cap investment offering high growth potential.

Return on Equity (ROE): 12.2% - Above-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for AtriCure, Inc. stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Accuracy scores show historical prediction reliability.

For AtriCure, Inc.: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for AtriCure, Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: AtriCure, Inc.'s competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For AtriCure, Inc.: Market positioning analysis based on available financial and operational metrics.

AtriCure, Inc. strategically competes in the highly dynamic Surgical & Medical Instruments & Apparatus marketplace, representing an emerging small-cap investment with substantial growth potential and market disruption capabilities .

The company maintains a healthy 646.2% gross margin, indicating strong pricing power and operational efficiency.

AtriCure, Inc. (ATRC) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for AtriCure, Inc. stock analysis.

Loading AtriCure, Inc. comprehensive fundamental analysis and insider trading data...

Deep dive into AtriCure, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if AtriCure, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For AtriCure, Inc.: With a P/E ratio of -39.61, the market sees the stock as potentially undervalued.

P/E Ratio -39.61x
P/B Ratio 4.00x
Market Cap $1857M
EPS $-0.77
Book Value/Share $9.35
Revenue/Share $10.06
FCF/Share $-0.88
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently AtriCure, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For AtriCure, Inc.: An ROE of 12.2% shows good shareholder value creation.

ROE 12.2%
ROA 8.1%
ROIC 11.2%
Gross Margin 646.2%
Operating Margin -65.9%
Net Margin -75.1%
EBT Margin 18.0%
Tax Rate 0.4%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess AtriCure, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For AtriCure, Inc.: A current ratio of 4.21 indicates strong liquidity.

Current Ratio 4.21x
Quick Ratio 3.21x
D/E Ratio 0.16x
Financial Leverage 1.26x
Interest Coverage 12.0x
Working Capital $258M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal AtriCure, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For AtriCure, Inc.: Free cash flow of $-41M indicates cash challenges that need attention.

Operating Cash Flow $-29M
Free Cash Flow $-41M
Capital Spending $-12M
FCF/Sales -14.1%
CapEx/Sales 4.1%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively AtriCure, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For AtriCure, Inc.: An asset turnover of 0.45x suggests room for improvement in asset utilization.

Asset Turnover 0.45x
Receivables Turnover 8.2x
Inventory Turnover 1.9x
Fixed Assets Turnover 8.7x
Days Sales Outstanding 44 days
Days Inventory 193 days
Payables Period 90 days
Cash Conversion Cycle 148 days
Understanding Financial Statement Data

What these metrics mean: Key figures from AtriCure, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For AtriCure, Inc.: With annual revenue of $499M, AtriCure, Inc. demonstrates solid business size.

Income Statement ($ Millions)
Total Revenue $499M
R&D Expense $82M
SG&A Expense $73M
Cost of Goods Sold $108M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 34%
Cash & Short-term Investments 19%
Total Liabilities 21%
Short-term Debt 1%
Accounts Receivable 7%
Inventory 7%
Dividend & Shareholder Information
Shares Outstanding 50M
Growth Metrics (YoY)
EPS Growth -2.6%

Latest AtriCure, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting AtriCure, Inc. (ATRC) stock price and investment outlook.

, source: Business Wire

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that Regina ...

, source: Yahoo Finance

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, ...

, source: Insider Monkey

The worries about the economic slowdown in China and the ongoing uncertainty about the path of interest-rate increases triggered several waves of equity sell-offs during the third quarter. Of course, ...

, source: Seeking Alpha

AtriCure educates and trains doctors in the proper use of its products and related technologies and does not educate or train doctors to use any of its products for the surgical treatment of AF.

, source: The Business Journals

One of the largest publicly traded companies in Miami Valley has named two new members to its board of directors. A publicly traded Warren County company has named two new members to its board of ...

, source: Insider Monkey

The worries about the economic slowdown in China and the ongoing uncertainty about the path of interest-rate increases triggered several waves of equity sell-offs during the third quarter. Of course, ...

AtriCure, Inc. Competitors & Peer Analysis - Industrial Applications and Services Sector

Comparative analysis of AtriCure, Inc. against industry peers and competitors in the Industrial Applications and Services sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ADGM Unlock Forecast - 30 Days FREE Trial $21M x 2.4x
ALUR Unlock Forecast - 30 Days FREE Trial $15M -0.4x -0.3x
ANGO Unlock Forecast - 30 Days FREE Trial $478M -1.4x 2.7x
ANIK Unlock Forecast - 30 Days FREE Trial $132M -4.3x 0.9x
AORT Unlock Forecast - 30 Days FREE Trial $1873M -198.2x 4.5x
APYX Unlock Forecast - 30 Days FREE Trial $110M -3.5x 15.2x
ATEC Unlock Forecast - 30 Days FREE Trial $2152M -7.4x 90.5x
ATRC Unlock Forecast - 30 Days FREE Trial $1857M -39.6x 4.0x
AVHHL Unlock Forecast - 30 Days FREE Trial $30M x x
BAX Unlock Forecast - 30 Days FREE Trial $11807M -94.9x 1.6x
BBNX Unlock Forecast - 30 Days FREE Trial $870M x 2.9x
BDX Unlock Forecast - 30 Days FREE Trial $53486M 33.7x 2.1x
BEAT Unlock Forecast - 30 Days FREE Trial $58M -5.7x 13.9x
BJDX Unlock Forecast - 30 Days FREE Trial $4M -0.5x 0.7x
BSX Unlock Forecast - 30 Days FREE Trial $146015M 58.3x 6.5x
BVS Unlock Forecast - 30 Days FREE Trial $458M -18.3x 2.8x
CARL Unlock Forecast - 30 Days FREE Trial $62M x x
CLPT Unlock Forecast - 30 Days FREE Trial $721M -23.5x 36.5x
CODX Unlock Forecast - 30 Days FREE Trial $12M -0.7x 0.3x
CVRX Unlock Forecast - 30 Days FREE Trial $260M -5.5x 4.5x
DCTH Unlock Forecast - 30 Days FREE Trial $418M 187.5x 4.0x
DRTS Unlock Forecast - 30 Days FREE Trial $319M x 3.7x
DXCM Unlock Forecast - 30 Days FREE Trial $26015M 45.5x 10.1x
EBRCZ Unlock Forecast - 30 Days FREE Trial $427M x 8.6x
FEMY Unlock Forecast - 30 Days FREE Trial $23M -1.4x 15.2x
FOFA Unlock Forecast - 30 Days FREE Trial $7M x 12.7x
GIPL Unlock Forecast - 30 Days FREE Trial $7M x 36.1x
GKOS Unlock Forecast - 30 Days FREE Trial $4885M -46.3x 6.4x
GMED Unlock Forecast - 30 Days FREE Trial $8091M 22.7x 1.9x
HRGN Unlock Forecast - 30 Days FREE Trial $29M x 38.2x
IART Unlock Forecast - 30 Days FREE Trial $1155M 200.2x 1.1x
ICCM Unlock Forecast - 30 Days FREE Trial $48M x 16.6x
ICUI Unlock Forecast - 30 Days FREE Trial $2926M -49.8x 1.4x
IDXG Unlock Forecast - 30 Days FREE Trial $4M 0.8x -0.9x
IINN Unlock Forecast - 30 Days FREE Trial $27M x 6.2x
IINNW Unlock Forecast - 30 Days FREE Trial $10M x 2.4x
INBS Unlock Forecast - 30 Days FREE Trial $8M -0.3x 2.5x
INFU Unlock Forecast - 30 Days FREE Trial $184M 36.2x 3.4x
INSP Unlock Forecast - 30 Days FREE Trial $2310M 43.5x 3.4x
IRMD Unlock Forecast - 30 Days FREE Trial $929M 45.0x 9.9x
IRTC Unlock Forecast - 30 Days FREE Trial $5812M -20.2x 56.1x
KIDS Unlock Forecast - 30 Days FREE Trial $402M -20.7x 1.1x
KMTS Unlock Forecast - 30 Days FREE Trial $1264M x x
KRMD Unlock Forecast - 30 Days FREE Trial $187M -19.8x 11.3x
LNSR Unlock Forecast - 30 Days FREE Trial $141M -6.7x -7.0x
LUCD Unlock Forecast - 30 Days FREE Trial $120M -0.6x 15.3x
LUNG Unlock Forecast - 30 Days FREE Trial $62M -4.3x 0.9x
MCAG Unlock Forecast - 30 Days FREE Trial $33M x -9.6x
MCAGU Unlock Forecast - 30 Days FREE Trial $31M x -9.9x
MDNC Unlock Forecast - 30 Days FREE Trial $59M 26.2x 12.2x
MDXG Unlock Forecast - 30 Days FREE Trial $970M 30.2x 4.5x
MGRM Unlock Forecast - 30 Days FREE Trial $217M -10.7x 25.1x
MHUA Unlock Forecast - 30 Days FREE Trial $11M x 0.1x
MMM Unlock Forecast - 30 Days FREE Trial $80645M 20.5x 18.8x
MMSI Unlock Forecast - 30 Days FREE Trial $4848M 40.7x 3.3x
NEPH Unlock Forecast - 30 Days FREE Trial $52M 39.1x 6.2x
NMTC Unlock Forecast - 30 Days FREE Trial $41M -1.7x 5.0x
NPCE Unlock Forecast - 30 Days FREE Trial $344M -10.4x 17.7x
NSPR Unlock Forecast - 30 Days FREE Trial $76M -4.3x 3.7x
NVCR Unlock Forecast - 30 Days FREE Trial $1531M -20.8x 4.4x
NXGL Unlock Forecast - 30 Days FREE Trial $20M -6.8x 4.3x
OBIO Unlock Forecast - 30 Days FREE Trial $128M -3.4x 1.3x
OFIX Unlock Forecast - 30 Days FREE Trial $595M -5.8x 1.3x
OSRH Unlock Forecast - 30 Days FREE Trial $11M x 0.1x
OSUR Unlock Forecast - 30 Days FREE Trial $223M 17.1x 0.6x
PAVM Unlock Forecast - 30 Days FREE Trial $10M 0.1x 0.3x
PDEX Unlock Forecast - 30 Days FREE Trial $86M 9.5x 2.3x
PEN Unlock Forecast - 30 Days FREE Trial $9954M 67.4x 7.7x
PLRZ Unlock Forecast - 30 Days FREE Trial $6M x 0.3x
PMI Unlock Forecast - 30 Days FREE Trial $90M x x
PODD Unlock Forecast - 30 Days FREE Trial $22506M 95.3x 15.4x
PRCT Unlock Forecast - 30 Days FREE Trial $1877M -45.4x 4.9x
PROF Unlock Forecast - 30 Days FREE Trial $166M x 4.2x
PYPD Unlock Forecast - 30 Days FREE Trial $51M x 2.5x
RCEL Unlock Forecast - 30 Days FREE Trial $106M -5.0x -29.9x
RDGL Unlock Forecast - 30 Days FREE Trial $35M x 13.0x
RMD Unlock Forecast - 30 Days FREE Trial $39524M 28.2x 6.6x
RSMDF Unlock Forecast - 30 Days FREE Trial $3625M 2.6x 0.6x
RTGN Unlock Forecast - 30 Days FREE Trial $66M x x
RVP Unlock Forecast - 30 Days FREE Trial $27M -0.9x 0.4x
SGHT Unlock Forecast - 30 Days FREE Trial $244M -3.7x 3.5x
SIBN Unlock Forecast - 30 Days FREE Trial $634M -14.3x 3.7x
SKIN Unlock Forecast - 30 Days FREE Trial $181M -1.8x 2.5x
SNOA Unlock Forecast - 30 Days FREE Trial $6M -5.6x 1.6x
SNWV Unlock Forecast - 30 Days FREE Trial $291M x -19.4x
SOLV Unlock Forecast - 30 Days FREE Trial $12387M 32.6x 3.4x
SRTS Unlock Forecast - 30 Days FREE Trial $53M 31.6x 1.0x
SSKN Unlock Forecast - 30 Days FREE Trial $8M -8.0x 25.6x
STIM Unlock Forecast - 30 Days FREE Trial $178M -1.0x 6.6x
STME Unlock Forecast - 30 Days FREE Trial $20M x x
STSS Unlock Forecast - 30 Days FREE Trial $5M -2.5x 0.3x
SYK Unlock Forecast - 30 Days FREE Trial $142678M 48.9x 12.2x
TCMD Unlock Forecast - 30 Days FREE Trial $324M 21.4x 1.7x
TELA Unlock Forecast - 30 Days FREE Trial $61M -1.8x 6.6x
TFX Unlock Forecast - 30 Days FREE Trial $5589M 29.1x 1.3x
TNDM Unlock Forecast - 30 Days FREE Trial $999M -17.1x 7.5x
TNON Unlock Forecast - 30 Days FREE Trial $9M -0.3x 1.4x
USAQ Unlock Forecast - 30 Days FREE Trial $2M x x
UTMD Unlock Forecast - 30 Days FREE Trial $191M 15.2x 1.6x
VERO Unlock Forecast - 30 Days FREE Trial $4M 0.0x 1.8x
WST Unlock Forecast - 30 Days FREE Trial $19211M 39.4x 6.6x
XTNT Unlock Forecast - 30 Days FREE Trial $99M -478.8x 2.0x

Frequently Asked Questions - AtriCure, Inc. Stock Forecast

How accurate are AtriCure, Inc. stock predictions?

Our AI model demonstrates 56% historical accuracy for ATRC predictions, based on advanced machine learning algorithms trained on over 10 years of market data.

What factors influence AtriCure, Inc. stock price forecasts?

Our analysis considers AtriCure, Inc.'s financial metrics, Industrial Applications and Services sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is AtriCure, Inc. a good investment in 2025?

Based on our AI analysis, AtriCure, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are AtriCure, Inc. forecasts updated?

AtriCure, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced AtriCure, Inc. Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for AtriCure, Inc. stock.

My Portfolio

Investment Dashboard

Loading your portfolio...